How long can you safely take Mounjaro — and what happens next?

You've been on Mounjaro for several months and you're wondering how long this goes on

It is a question our prescribers hear regularly, often from people who are doing well and feeling slightly uneasy about being on a medicine indefinitely. The underlying concern is understandable. Most medicines people associate with weight loss have come with short courses and clear end-points, so the idea of open-ended treatment can feel unfamiliar.

The reality is that tirzepatide is licensed for weight management as an ongoing intervention, not as a short course. The NHS patient information for tirzepatide does not set a cut-off date, and neither does the medicine's SmPC. What both emphasise is that treatment should continue only while it remains clinically appropriate, which means your prescriber checks this at every review rather than assuming it will go on forever by default.

The SURMOUNT clinical programme, involving thousands of adults across its trials, studied participants for up to 72 weeks and found that weight loss continued to accrue over that period rather than plateauing early. That tells us the medicine keeps working well beyond the first few months at a maintenance dose. If you want a fuller answer to how long you can take Mounjaro, including what the evidence and guidance say about extended use, that page brings everything together in one place.

You can read more about how quickly tirzepatide tends to produce results and what to expect in the early weeks of treatment.

The 6-month review: what NICE says about carrying on

NICE published its recommendation for tirzepatide in December 2024 (TA1026, updated September 2025). One of its clearest practical statements concerns people who are not responding as expected: if you have not lost at least 5% of your starting body weight after six months at the highest dose your body tolerates, the guidance recommends reviewing whether continuing makes sense.

That threshold is not a punishment for slow progress. It reflects the clinical judgement that the medicine needs to be producing meaningful benefit to justify ongoing use. For most people who do respond well, the guidance does not impose a ceiling. Treatment continues while benefit is maintained and the clinical picture supports it.

There is a common misconception worth naming here: that Mounjaro is only ever prescribed for a short bridging period, perhaps six months, and then you are expected to manage alone. The licensed indication does not work that way. Weight is a condition shaped by physiology, and the prescriber's job is to match the treatment to the individual's needs, which may mean continuing for longer or tapering once a stable lower weight has been maintained. Neither outcome is predetermined.

The NICE tirzepatide recommendations (TA1026, section 1) are publicly available and worth reading if you want the precise clinical language.

What stopping looks like, and why the plan matters

Deciding to stop Mounjaro is as much of a clinical decision as deciding to start. Research across GLP-1 medicines consistently shows that appetite tends to return when treatment ends, and weight regain is common without a plan in place. This is not a failure of willpower; it reflects how the body responds to losing a pharmacological signal that had been influencing hunger hormones.

A thoughtful stopping strategy, developed with your prescriber, usually involves timing the step-down to a point where lifestyle habits are well established, weight has been stable for some time, and there is a clear plan for what comes next. Some people choose to stay on a lower maintenance dose rather than stopping completely. Others stop entirely and continue with the dietary and activity changes they have built during treatment. Both are legitimate paths, and neither should be rushed.

If you are thinking about how to approach this stage, the guide to coming off Mounjaro safely covers what the process involves in more detail. And if you are still at an earlier stage and thinking about how long you might realistically need to stay on treatment, the overview of how long people take Mounjaro for gives a broader picture.

For those curious about what happens to the medicine itself after a dose, the page on how long tirzepatide remains active in the body explains the pharmacology in plain terms.

Safety, monitoring, and what to keep in mind during long-term treatment

Staying on any prescription medicine for an extended period involves ongoing monitoring. With tirzepatide, the main areas to keep an eye on are the side effects that tend to settle early for most people (nausea, digestive changes) but occasionally persist, and the less common but more serious signals that warrant prompt attention. Severe stomach pain that radiates to the back, signs of a gallbladder problem, or any symptoms that feel distinctly different from your usual experience should always prompt contact with a clinician rather than a wait-and-see approach.

Patients can report any suspected side effects through the MHRA Yellow Card scheme, which collects safety data on medicines including tirzepatide throughout its licensed use. This is a genuine resource, not just a formality.

At nume, a GPhC-registered prescriber reads your notes before every repeat is issued. There is no auto-renewal. If your progress has stalled, your circumstances have changed, or a concern has emerged, that review is the point at which it gets picked up. You can see how our clinical team approaches these decisions on our prescriber's profile page.

If you are thinking about the financial side of a longer treatment course, our Mounjaro pricing page sets out what the cost covers, with no hidden fees and no subscription structure that keeps charging without review.

Ready to talk through your situation? Check your eligibility with a free consultation and a prescriber will look at where you are and what makes sense for you.